Treatment for diabetes and NASH with a combination of pioglitazone and either a GLP-1 receptor agonist or SGLT-2 inhibitor may be a cost-effective strategy while lowering the increased cardiovascular risks in this patient population (94). Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.